Lv4
730 积分 2021-03-06 加入
Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial
9天前
已完结
Multicenter, retrospective GUIDANCE001 study comparing transarterial chemoembolization with or without tyrosine kinase and immune checkpoint inhibitors as conversion therapy to treat unresectable hepatocellular carcinoma: Survival benefit in intermediate or advanced, but not early, stages
9天前
已完结
Anlotinib plus penpulimab versus sorafenib in the first-line treatment of unresectable hepatocellular carcinoma (APOLLO): a randomised, controlled, phase 3 trial
9天前
已完结
Complete Response to Locoregional Therapy Plus Immunotherapy for Hepatocellular Carcinoma
11天前
已完结
Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial
11天前
已完结
Small-molecule-based targeted therapy in liver cancer
13天前
已完结
Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial
17天前
已完结
Immunotherapies for hepatocellular carcinoma
17天前
已完结
Evolving therapeutic landscape of advanced hepatocellular carcinoma
17天前
已完结
Critical Appraisal of Guideline Recommendations on Systemic Therapies for Advanced Hepatocellular Carcinoma
17天前
已完结
皖公网安备34019202002308
